

## Supplementary Online Content

Chlebowski RT, Anderson GL, Gass M, et al; WHI Investigators. Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women. *JAMA*. 2010;304(15):1684-1692.

**eTable 1.** Baseline Characteristics of All Trial Participants by Randomization Group

**eTable 2.** Baseline Characteristics of Trial Participants Who Reconsented by Randomization Group

**eTable 3.** Number and Percentage of All Eligible Participants From the Original Population Who Consented by Baseline Characteristics and Randomization Group

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1.** Baseline Characteristics of All Trial Participants by Randomization Group (n=16 608)

	Combined hormone therapy (n=8506)		Placebo (n=8102)		P-Value
	N	%	N	%	
Age group at screening					0.79
50-59	2837	33.4	2683	33.1	
60-69	3854	45.3	3655	45.1	
70-79	1815	21.3	1764	21.8	
Race/ethnicity					0.31
White	7141	84.0	6805	84.0	
Black	548	6.4	574	7.1	
Hispanic	471	5.5	415	5.1	
American Indian	25	0.3	30	0.4	
Asian/Pacific Islander	194	2.3	169	2.1	
Unknown	127	1.5	109	1.3	
Education					0.19
0-8 years	202	2.4	177	2.2	
Some high school	373	4.4	362	4.5	
High school diploma/GED	1615	19.1	1609	20.0	
School after high school	3357	39.7	3060	38.0	
College degree or higher	2915	34.4	2839	35.3	
Gail 5-year risk					0.76
< 1.25	2806	33.0	2717	33.5	
1.25 - < 1.75	2859	33.6	2703	33.4	
≥ 1.75	2841	33.4	2682	33.1	
Age at menarche					0.83
≤11	1725	20.3	1670	20.7	
12-13	4578	54.0	4334	53.7	
≥ 14	2182	25.7	2061	25.6	
Years since menopause					0.49
< 5 yrs	1313	17.1	1225	16.3	
5 - <10 yrs	1467	19.1	1486	19.8	
10 - <15 yrs	1613	21.0	1567	20.9	
≥ 15 yrs	3286	42.8	3230	43.0	
Number of term pregnancies					0.38
Never pregnant/Never had term pregnancy	860	10.2	833	10.3	
1	690	8.1	661	8.2	
2	1908	22.5	1708	21.2	
3	2020	23.9	1952	24.2	
4	1416	16.7	1412	17.5	
5+	1575	18.6	1500	18.6	
Age at first birth, y (categories)					0.18
Never pregnant/No term pregnant	860	11.2	833	11.5	
< 20	1124	14.6	1117	15.4	
20 - 29	4996	64.8	4698	64.6	
30+	727	9.4	624	8.6	
Number of months breastfed					0.82
Never brstfd	3813	45.3	3669	45.8	
brstfd ≤ 1 year	3150	37.5	2971	37.1	
brstfd > 1 year	1446	17.2	1366	17.1	
Oral contraceptive use ever	3695	43.4	3447	42.5	0.24
Oral contraceptive duration					0.25
< 5 yrs	1982	53.7	1781	51.7	
5 - < 10 yrs	825	22.3	808	23.5	
≥ 10 yrs	886	24.0	855	24.8	
HRT use status					0.45
Never used	6277	73.8	6022	74.4	
Past user	1671	19.7	1587	19.6	
Current user	554	6.5	490	6.1	
Unopposed estrogen use ever	903	10.6	865	10.7	0.90
Unopposed estrogen use					0.81
Non-user	7603	89.4	7237	89.3	
< 5 yrs	677	8.0	659	8.1	
≥ 5 yrs	226	2.7	205	2.5	
Estrogen + progesterone use ever	1516	17.8	1396	17.2	0.32

**eTable 1.** Baseline Characteristics of All Trial Participants by Randomization Group (n=16 608) (continued)

	Combined hormone therapy (n=8506)		Placebo (n=8102)		P-Value
	N	%	N	%	
Estrogen + Progest Duration					0.27
Non-user	6990	82.2	6706	82.8	
< 5 yrs	1050	12.3	997	12.3	
≥ 5 yrs	466	5.5	399	4.9	
Time since quitting HT					0.58
Current	554	6.5	490	6.1	
Past, < 5 yrs	726	8.5	673	8.3	
Past, ≥ 5 yrs	945	11.1	914	11.3	
Never	6277	73.8	6022	74.4	
Number of first deg female relatives with breast cancer					0.23
None	6954	87.3	6676	88.2	
1	927	11.6	816	10.8	
2 or more	82	1.0	79	1.0	
Benign breast disease					0.86
No	6340	83.6	6278	83.3	
Yes, 1 biopsy	956	12.6	972	12.9	
Yes, 2+ biopsies	290	3.8	288	3.8	
Body-mass index (kg/m <sup>2</sup> ), baseline					0.89
< 25	2579	30.4	2479	30.8	
25 - < 30	2992	35.3	2835	35.2	
≥ 30	2899	34.2	2737	34.0	
Dietary energy(kcal)					0.40
≤ 1322 kcal	2687	32.7	2610	33.3	
1322 < - 1841 kcal	2779	33.8	2678	34.2	
> 1841 kcal	2752	33.5	2545	32.5	
Percent energy from fat					0.46
≤ 29.6 percent	2709	33.0	2588	33.0	
29.6 < - 37.2 percent	2764	33.6	2694	34.4	
> 37.2 percent	2745	33.4	2551	32.6	
Physical act (METS/wk)					0.73
≤ 3.5 METS/wk	2658	34.6	2603	34.3	
3.5 < - 12.8 METS/wk	2508	32.7	2467	32.5	
> 12.8 METS/wk	2505	32.7	2526	33.3	
Alcohol use					0.25
Non Drinker	3601	42.5	3471	43.0	
≤ 1 drink/day	3821	45.1	3546	44.0	
> 1 drink/day	1047	12.4	1048	13.0	
Smoking status					0.85
Never	4178	49.6	3999	50.0	
Past	3362	39.9	3157	39.5	
Current	880	10.5	838	10.5	
NSAIDs	2853	33.5	2767	34.2	0.41

Due to information missing for some variables, category denominators do not always equal group total shown in column heading.

Gail risk score incorporates age, history of benign disease (atypia status unknown in the Women's Health Initiative), age at menarche, age at first live birth, race/ethnicity, and numbers of mothers and sisters with breast cancer

NSAIDs = use of aspirin, ibuprofen, prescription NSAIDs, or the related analgesic, acetaminophen

Time from menopause was defined as previously described<sup>15</sup>, as the interval from the onset of menopause to first menopausal hormone therapy use or first use of study medication (hormone or placebo).

**eTable 2.** Baseline Characteristics of Trial Participants Who Reconsented by Randomization Group (n=12 788)

	Combined hormone therapy (n=6545)		Placebo (n=6243)		P-Value
	N	%	N	%	
Age group at screening					0.75
50-59	2266	34.6	2128	34.1	
60-69	3019	46.1	2887	46.2	
70-79	1260	19.3	1228	19.7	
Race/ethnicity					0.97
White	5616	85.8	5357	85.8	
Black	406	6.2	401	6.4	
Hispanic	291	4.4	261	4.2	
American Indian	16	0.2	14	0.2	
Asian/Pacific Islander	132	2.0	128	2.1	
Unknown	84	1.3	82	1.3	
Education					0.27
0-8 years	94	1.4	90	1.5	
Some high school	230	3.5	238	3.8	
High school diploma/GED	1254	19.3	1225	19.8	
School after high school	2569	39.5	2329	37.6	
College degree or higher	2363	36.3	2317	37.4	
Gail 5-year risk					0.91
< 1.25	2117	32.3	2041	32.7	
1.25 - < 1.75	2237	34.2	2125	34.0	
≥ 1.75	2191	33.5	2077	33.3	
Age at menarche					0.79
≤11	1372	21.0	1279	20.6	
12-13	3539	54.2	3377	54.3	
≥ 14	1617	24.8	1563	25.1	
Years since menopause					0.52
< 5 yrs	1071	18.0	988	17.0	
5 - <10 yrs	1199	20.2	1206	20.8	
10 - <15 yrs	1267	21.3	1242	21.4	
≥ 15 yrs	2410	40.5	2370	40.8	
Number of term pregnancies					0.37
Never pregnant/Never had term pregnancy	661	10.1	627	10.1	
1	529	8.1	488	7.9	
2	1480	22.7	1319	21.2	
3	1573	24.1	1538	24.7	
4	1104	16.9	1103	17.7	
5+	1171	18.0	1140	18.3	
Age at first birth, y (categories)					0.30
Never pregnant/No term pregnant	661	11.1	627	11.1	
< 20	825	13.8	820	14.6	
20 - 29	3913	65.6	3702	65.7	
30+	564	9.5	482	8.6	
Number of months breastfed					0.96
Never brstfd	2912	44.9	2782	45.1	
brstfd ≤ 1 year	2416	37.3	2285	37.0	
brstfd > 1 year	1152	17.8	1103	17.9	
Oral contraceptive use ever	2960	45.2	2789	44.7	0.53
Oral contraceptive duration					0.47
< 5 yrs	1564	52.9	1438	51.6	
5 - < 10 yrs	669	22.6	667	23.9	
≥ 10 yrs	726	24.5	681	24.4	
HRT use status					0.64
Never used	4798	73.3	4619	74.0	
Past user	1282	19.6	1200	19.2	
Current user	462	7.1	421	6.7	

**eTable 2.** Baseline Characteristics of Trial Participants Who Reconsented by Randomization Group (n=12 788) (continued)

	Combined hormone therapy (n=6545)		Placebo (n=6243)		P-Value
	N	%	N	%	
Unopposed estrogen use ever	682	10.4	645	10.3	0.87
Unopposed estrogen use					0.88
Non-user	5863	89.6	5598	89.7	
< 5 yrs	518	7.9	496	7.9	
≥ 5 yrs	164	2.5	148	2.4	
Estrogen + progesterone use ever	1215	18.6	1131	18.1	0.51
Estrogen + Progest Duration					0.61
Non-user	5330	81.4	5112	81.9	
< 5 yrs	840	12.8	798	12.8	
≥ 5 yrs	375	5.7	333	5.3	
Time since quitting HT					0.80
Current	462	7.1	421	6.7	
Past, < 5 yrs	576	8.8	531	8.5	
Past, ≥ 5 yrs	706	10.8	669	10.7	
Never	4798	73.3	4619	74.0	
Number of first deg female relatives with breast cancer					0.30
None	5371	87.4	5149	88.1	
1	715	11.6	633	10.8	
2 or more	58	0.9	63	1.1	
Benign breast disease					0.79
No	4904	83.6	4843	83.2	
Yes, 1 biopsy	740	12.6	759	13.0	
Yes, 2+ biopsies	222	3.8	218	3.7	
Body-mass index (kg/m <sup>2</sup> ), baseline					0.19
< 25	1998	30.7	1949	31.4	
25 - < 30	2278	35.0	2215	35.7	
≥ 30	2240	34.4	2038	32.9	
Dietary energy(kcal)					0.43
≤ 1322 kcal	1996	31.5	1966	32.4	
1322 < - 1841 kcal	2215	34.9	2117	34.9	
> 1841 kcal	2130	33.6	1980	32.7	
Percent energy from fat					0.44
≤ 29.6 percent	2157	34.0	2065	34.1	
29.6 < - 37.2 percent	2114	33.3	2077	34.3	
> 37.2 percent	2070	32.6	1921	31.7	
Physical act (METS/wk)					0.46
≤ 3.5 METS/wk	1996	33.7	1913	32.7	
3.5 < - 12.8 METS/wk	1940	32.8	1936	33.0	
> 12.8 METS/wk	1987	33.5	2010	34.3	
Alcohol use					0.76
Non Drinker	2671	41.0	2559	41.1	
≤ 1 drink/day	3003	46.1	2832	45.5	
> 1 drink/day	844	12.9	828	13.3	
Smoking status					0.94
Never	3288	50.7	3139	50.9	
Past	2597	40.0	2452	39.8	
Current	600	9.3	577	9.4	
NSAIDs	2194	33.5	2133	34.2	0.44

Due to information missing for some variables, category denominators do not always equal group total shown in column heading.

Gail risk score incorporates age, history of benign disease (atypia status unknown in the Women's Health Initiative), age at menarche, age at first live birth, race/ethnicity, and numbers of mothers and sisters with breast cancer

NSAIDs = use of aspirin, ibuprofen, prescription NSAIDs, or the related analgesic, acetaminophen

Time from menopause was defined as previously described<sup>15</sup>, as the interval from the onset of menopause to first menopausal hormone therapy use or first use of study medication (hormone or placebo).

**eTable 3.** Number and Percentage of All Eligible Participants From the Original Population Who Consented by Baseline Characteristics and Randomization Group

	Combined hormone therapy (n=7878 eligible)		Placebo (n=7530 eligible)		P-Value
	N	%	N	%	
<b>Overall</b>	<b>6545</b>	<b>83.1</b>	<b>6243</b>	<b>82.9</b>	<b>0.78</b>
Age group at screening					0.86
50-59	2266	84.0	2128	83.8	
60-69	3019	84.1	2887	84.3	
70-79	1260	79.2	1228	78.5	
Race/ethnicity					0.11
White	5616	85.0	5357	84.5	
Black	406	80.2	401	77.1	
Hispanic	291	65.1	261	66.9	
American Indian	16	66.7	14	56.0	
Asian/Pacific Islander	132	74.2	128	82.6	
Unknown	84	72.4	82	82.0	
Education					0.46
0-8 years	94	51.4	90	57.3	
Some high school	230	71.4	238	72.6	
High school diploma/GED	1254	83.7	1225	81.6	
School after high school	2569	82.5	2329	82.7	
College degree or higher	2363	86.8	2317	86.7	
Gail 5year risk					0.54
< 1.25	2117	80.2	2041	80.1	
1.25 - < 1.75	2237	84.4	2125	85.0	
≥ 1.75	2191	84.7	2077	83.7	
Age at menarche					0.04
≤11	1372	85.5	1279	82.5	
12-13	3539	83.4	3377	83.8	
≥ 14	1617	80.4	1563	81.6	
Years since menopause					0.54
< 5 yrs	1617	85.3	1563	84.6	
5 - <10 yrs	1071	86.3	988	85.4	
10 - <15 yrs	1199	83.2	1206	84.7	
≥ 15 yrs	1267	81.2	1242	80.5	
Number of term pregnancies					0.51
Never pregnant/Never had term pregnancy	661	83.0	627	82.8	
Mean ± SD	529	83.0	488	80.1	
Age at first birth, y (categories)					>0.99
Never pregnant/No term pregnant	661	83.0	627	82.8	
< 20	825	80.6	820	80.0	
20 - 29	3913	84.4	3702	84.1	
30+	564	84.3	482	83.7	
Number of months breastfed					0.70
Never brstfd	2912	82.7	2782	81.8	
brstfd ≤ 1 year	2416	82.7	2285	83.0	
brstfd > 1 year	1152	85.6	1103	85.5	
Oral contraceptive use ever	2960	85.4	2789	85.7	0.50
Oral contraceptive duration					0.36
< 5 yrs	1564	84.4	1438	85.7	
5 - < 10 yrs	669	86.0	667	86.1	
≥ 10 yrs	726	86.9	681	85.2	

**eTable 3.** Number and Percentage of All Eligible Participants From the Original Population Who Consented by Baseline Characteristics and Randomization Group (continued)

	Combined hormone therapy (n=7878 eligible)		Placebo (n=7530 eligible)		P-Value
	N	%	N	%	
Unopposed estrogen use ever	682	82.5	645	81.5	0.68
Unopposed estrogen use					0.59
Non-user	5863	83.3	5598	81.3	
< 5 yrs	518	83.2	496	83.1	
≥ 5 yrs	164	80.0	148	82.2	
Estrogen + progesterone use ever	1215	85.0	1131	85.9	0.40
Estrogen + Progest Duration					0.67
Non-user	5330	82.6	5112	82.3	
< 5 yrs	840	84.4	798	85.3	
≥ 5 yrs	375	86.4	333	87.6	
Number of first deg female relatives with breast cancer					0.74
None	5371	84.9	5149	84.7	
1	715	83.1	633	82.8	
2 or more	58	80.6	63	85.1	
Benign breast disease					0.89
No	4904	83.1	4843	83.0	
Yes, 1 biopsy	740	84.6	759	83.6	
Yes, 2+ biopsies	222	82.2	218	81.3	
Body-mass index (kg/m <sup>2</sup> ), baseline					0.03
< 25	1998	84.4	1949	84.1	
25 - < 30	2278	81.9	2215	83.6	
≥ 30	2240	83.1	2038	80.9	
Dietary energy(kcal)					0.96
≤ 1322 kcal	1996	80.8	1966	80.7	
1322 < - 1841 kcal	2215	85.0	2117	85.2	
> 1841 kcal	2130	83.6	1980	83.6	
Percent energy from fat					0.78
≤ 29.6 percent	2157	85.5	2065	84.8	
29.6 < - 37.2 percent	2114	82.8	2077	83.0	
> 37.2 percent	2070	81.3	1921	81.6	
Physical act (METs/wk)					0.85
≤ 3.5 METs/wk	1996	81.4	1913	80.5	
3.5 < - 12.8 METs/wk	1940	83.7	1936	83.6	
> 12.8 METs/wk	1987	84.7	2010	84.7	
Alcohol use					0.54
Non Drinker	2671	80.5	2559	80.3	
≤ 1 drink/day	3003	84.4	2832	84.7	
> 1 drink/day	844	87.3	828	85.7	
Smoking status					0.63
Never	3288	83.1	3139	83.3	
Past	2597	84.1	2452	83.9	
Current	600	79.4	577	77.3	
NSAIDs	2194	83.5	2133	83.4	0.96

Due to information missing for some variables, category denominators do not always equal group total shown in column heading.

Gail risk score incorporates age, history of benign disease (atypia status unknown in the Women's Health Initiative), age at menarche, age at first live birth, race/ethnicity, and numbers of mothers and sisters with breast cancer

NSAIDs = use of aspirin, ibuprofen, prescription NSAIDs, or the related analgesic, acetaminophen

Time from menopause was defined as previously described<sup>15</sup>, as the interval from the onset of menopause to first menopausal hormone therapy use or first use of study medication (hormone or placebo).

As seen, consent rates were comparable for demographic and risk factor distribution for the two randomization groups.